Brainstorm Cell Therapeutics Overview
- Year Founded
-
2000
- Status
-
Public
- Employees
-
27
- Stock Symbol
-
BCLI
- Share Price
-
$0.97
- (As of Friday Closing)
Brainstorm Cell Therapeutics General Information
Description
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Contact Information
Website
www.brainstorm-cell.comCorporate Office
- 1325 Avenue of Americas
- 28th Floor
- New York, NY 10019
- United States
Corporate Office
- 1325 Avenue of Americas
- 28th Floor
- New York, NY 10019
- United States
Brainstorm Cell Therapeutics Timeline
Brainstorm Cell Therapeutics Stock Performance
As of 25-Apr-2025, Brainstorm Cell Therapeutics’s stock price is $0.97. Its current market cap is $6.36M with 6.52M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.97 | $0.92 | $0.72 - $10.05 | $6.36M | 6.52M | 142K | -$2.31 |
Brainstorm Cell Therapeutics Financials Summary
As of 31-Dec-2024, Brainstorm Cell Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 31-Dec-2024 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 |
|---|---|---|---|---|
| EV | 13,620 | 13,620 | 14,845 | 56,914 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (11,306) | (11,306) | (16,480) | (24,537) |
| Net Income | (11,623) | (11,623) | (17,192) | (24,277) |
| Total Assets | 1,832 | 1,832 | 4,208 | 8,451 |
| Total Debt | 720 | 720 | 1,275 | 4,093 |
Brainstorm Cell Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Brainstorm Cell Therapeutics Comparisons
Industry
Financing
Details
Brainstorm Cell Therapeutics Competitors (30)
One of Brainstorm Cell Therapeutics’s 30 competitors is CuraSen, a Venture Capital-Backed company based in San Carlos, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CuraSen | Venture Capital-Backed | San Carlos, CA | ||||
| NeuroNascent | Venture Capital-Backed | Clarksville, MD | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA | ||||
| ProMIS Neurosciences | Corporation | Toronto, Canada | ||||
| Neurogene | Formerly VC-backed | New York, NY |
Brainstorm Cell Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Brainstorm Cell Therapeutics Patents
Brainstorm Cell Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4367220-A1 | Methods of generating mesenchyal stem cells which secrete neurotrophic factors in a bioreactor system | Pending | 06-Jul-2021 | ||
| US-20240327795-A1 | Methods of generating mesenchyal stem cells which secrete neurotrophic factors in a bioreactor system | Pending | 06-Jul-2021 | ||
| EP-4181935-A1 | Methods and compositions for treating lung conditions | Pending | 20-Jul-2020 | ||
| CA-3189818-A1 | Methods and compositions for treating lung conditions | Pending | 20-Jul-2020 | ||
| AU-2021313472-A1 | Methods and compositions for treating lung conditions | Pending | 20-Jul-2020 | A61K35/28 |
Brainstorm Cell Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Brainstorm Cell Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Brainstorm Cell Therapeutics ESG
Risk Overview
Risk Rating
Updated April, 14, 2021
27.48 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 14,042
Rank
Percentile
Technology Hardware
Industry
of 557
Rank
Percentile
Technology Hardware
Subindustry
of 101
Rank
Percentile
Brainstorm Cell Therapeutics FAQs
-
When was Brainstorm Cell Therapeutics founded?
Brainstorm Cell Therapeutics was founded in 2000.
-
Where is Brainstorm Cell Therapeutics headquartered?
Brainstorm Cell Therapeutics is headquartered in New York, NY.
-
What is the size of Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics has 27 total employees.
-
What industry is Brainstorm Cell Therapeutics in?
Brainstorm Cell Therapeutics’s primary industry is Biotechnology.
-
Is Brainstorm Cell Therapeutics a private or public company?
Brainstorm Cell Therapeutics is a Public company.
-
What is Brainstorm Cell Therapeutics’s stock symbol?
The ticker symbol for Brainstorm Cell Therapeutics is BCLI.
-
What is the current stock price of Brainstorm Cell Therapeutics?
As of 25-Apr-2025 the stock price of Brainstorm Cell Therapeutics is $0.97.
-
What is the current market cap of Brainstorm Cell Therapeutics?
The current market capitalization of Brainstorm Cell Therapeutics is $6.36M.
-
Who are Brainstorm Cell Therapeutics’s competitors?
CuraSen, NeuroNascent, Vertex Pharmaceuticals, ProMIS Neurosciences, and Neurogene are some of the 30 competitors of Brainstorm Cell Therapeutics.
-
What is Brainstorm Cell Therapeutics’s annual earnings per share (EPS)?
Brainstorm Cell Therapeutics’s EPS for 12 months was -$2.31.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
